LEIDEN, Netherlands, April 29, 2005 (PRIMEZONE) -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext:PHARM) (PHAR.AS) announced today that the Company is the beneficiary of over 800,000 Pharming shares. These shares stem from Stichting Pharming Trust Beheer ("SPTB"), a foundation which has agreed today to transfer these shares to Pharming. SPTB has been dissolved as of April 29, 2005.
SPTB was founded on December 23, 1998 to hold unclaimed Pharming shares. SPTB held these shares for beneficiaries thereto until the expiration date of April 28, 2005. With the dissolution of SPTB, the shares return to Pharming Group N.V.
Background on Pharming Group N.V.
Pharming Group N.V. is developing innovative protein therapeutics for unmet medical needs. The Company's products include potential treatments for genetic disorders, specialty products for surgical indications, and intermediates for various applications. Pharming's lead product (recombinant human C1 inhibitor) for hereditary angioedema is in Phase III of clinical development. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, as well as technology and processes for the purification and formulation of these products. Additional information is available on the Pharming website, http://www.pharming.com.
This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.
http://hugin.info/132866/R/992186/149697.pdf
-0-
-0- Pharming Group N.V. Samir Singh T: + 31-(0)71-524-7431 T: + 1-908-720-6224